CTOs on the Move

Medexus

www.medexus.com

 
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.medexus.com
  • 35 Nixon Road Unit 1
    Bolton, ON CAN L7E 1K1
  • Phone: 877.633.3987

Executives

Name Title Contact Details

Similar Companies

Proacta

Proacta Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wockhardt USA

Wockhardt USA is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WellSpring Pharmaceutical Corporation

WellSpring Pharmaceutical Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flowr Corporation

The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.

Pieris

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.